This edition highlights some developments in the licensing of standard essential patents (SEPs) on “fair, reasonable, and non-discriminatory" (FRAND) terms. Furthermore, it provides insight into the new Intellectual Property Report of KPMG Law, analyzing developments and trends in top international IP departments. Featured are also the continuations of the Brexit series and the analysis of the impact of the latest patent reform in China on developments in the pharmaceutical industries. Reports on new legislative initiatives in various jurisdictions, analyses of recent court decisions and news will complete the picture.
